Investor Relations

Welcome/AIM Rules

Plethora's strategy is focused on bringing Fortacin™ to market via partners with the sales, marketing and distribution infrastructure to maximize the commercial potential from the product. In this respect, Plethora is engaged in dialogue with multiple parties, including major pharmaceutical companies, for a launch of Fortacin™, with the initial focus being on markets within the European Union, the United States (subject to regulatory approval) and other selected territories.

This area of the site contains all information required to be disclosed in accordance with Rule 26 of the AIM Rules. The Investor Relations section of this website was last updated on 31 October 2015.